Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446081 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL29773884 | 0.84 | NAPRT (0.47) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL979398 | 0.84 | NAPRT (0.47) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL28662886 | 0.84 | NNMT (0.42) | SMN1; SMN2TSHRCASP1NAPRTHAVCR2 | |
| SCHEMBL29577063 | 0.84 | NNMT (0.42) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL16333365 | 0.84 | NNMT (0.42) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL1300053 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL29411268 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL29186263 | 0.83 | NAPRT (0.45) | SMN1; SMN2TSHRCASP1NAPRTALDH1A1 | |
| SCHEMBL3240453 | 0.81 | ASPH (0.55) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106854177-A | A kind of preparation method of the formaldehyde of 6 chlorine, 4 pyridone 3 | 苏州健雄职业技术学院 | 2017-06-16 | — | — | CN | claimed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1066286-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999045009-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-10 | — | — | WO | disclosed |
| US-4191831-A | BACTERICIDES | E. R. SQUIBB & SONS, INC. (US) | 1980-03-04 | — | — | US | disclosed |
| US-4075210-A | Pyrazolo[1,5-a]pyrido[4,3-d]pyrimidin-9(4H)-one and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4066645-A | Derivatives of pyrazolo [1,5-a]pyrido[3,4-e]pyrimidine | E. R. SQUIBB & SONS, INC. (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | SMN1; SMN2 1897/4885TSHR 256/4885CASP1 3421/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | SMN1; SMN2 2386/4885TSHR 1503/4885CASP1 1690/4885 |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SMN1; SMN2 738/4885TSHR 1088/4885CASP1 2659/4885 |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1540/4885TSHR 1625/4885CASP1 223/4885 |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | SMN1; SMN2 745/4885TSHR 567/4885CASP1 70/4885 |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | SMN1; SMN2 3561/4885TSHR 168/4885CASP1 1653/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | SMN1; SMN2 1077/4885TSHR 31/4885CASP1 1943/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | SMN1; SMN2 1972/4885TSHR 469/4885CASP1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.